This systematic review supports the use of non-steroidal anti-androgens in high-risk non-metastatic castrate-resistant prostate cancer. Indirect comparison suggests there are important differences in oncologic outcomes between agents. Treatment selection will depend on patient and physician appraisal of the relative efficacy and toxicity of each agent.
- Drug-related side effects and adverse reactions
- Nonsteroidal anti-androgens
- Prostatic neoplasms
ASJC Scopus subject areas